Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
on Wednesday said its wholly- owned arm
Eugia Pharma Specialities
Ltd has received final approval from the USFDA to manufacture and market its generic version of
Dasatinib tablets
indicated in certain types of cancer of bone marrow and blood.
The approval by the US Food & Drug Administration (USFDA) is for manufacturing and marketing of Dasatinib tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Aurobindo Pharma said in a regulatory filing.
These are bioequivalent and therapeutically equivalent to the reference listed drug
Sprycel Tablets
in the same strengths, of
Bristol-Myers Squibb
Company (BMS), it added.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
If You Eat Ginger Everyday for 1 Month This is What Happens
Tips and Tricks
Undo
The product is expected to be launched in Q1FY26, Aurobindo Pharma said.
The approved product has an estimated market size of USD 1.8 billion for the 12 months ended February 2025, it said citing IQVIA MAT data.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
20 minutes ago
- Economic Times
From hype to value: Indian IPOs offer better valuation comfort in 2025, says Sreeram Ramdas
After a frenzied run of overhyped IPOs in recent years, India's primary market seems to be undergoing a meaningful shift. In this edition of ETMarkets Smart Talk, Sreeram Ramdas, Vice President at Green Portfolio, shares how 2025 is shaping up to be a year of value-driven public issues rather than momentum-led listings. He highlights how investor caution, fewer aggressive valuations, and stronger fundamentals are helping restore balance in the IPO space, offering better comfort to long-term investors. Edited Excerpts - ADVERTISEMENT Q) The second half of 2025 started on a volatile note. How are you looking at the markets? One of the reasons could be FIIs selling, which continues in July. A) While FII selling is certainly a contributing factor, we don't believe it's the sole reason for the market's recent volatility. We see three primary drivers behind the market's pronounced reactions over the past few days. First, the initial earnings reports from top-tier Nifty companies have fallen short of expectations. In the banking sector, for instance, we saw weak numbers from Axis Bank, driven by an increase in provisions. In IT, TCS only managed to post positive year-on-year revenue growth thanks to favourable USD/INR currency fluctuations. Second, and what we consider the most significant factor, is the mounting uncertainty surrounding the trade deal with the US. As we approach the August 1st deadline, the markets are growing increasingly sceptical. ADVERTISEMENT Finally, we're observing foreign institutions downgrading Indian markets, labelling them as expensive, which has prompted the FII selling you mentioned. These are the main reasons why Indian markets are likely to remain volatile and range-bound for the time being.Q) IPOs have picked up recently, but EY report highlighted that Indian IPO activity in the first half of 2025 recorded 108 deals raising US$4.6b, demonstrating market resilience despite a 30% decline in transactions.A) This is exactly the kind of IPO market we've been waiting for. The sharp decline in IPO volume and the fewer companies ringing the bell are positive, not negatives. ADVERTISEMENT From a valuation standpoint, we're now seeing EV scooter manufacturers approaching the market with a more reasonable 11x price-to-earnings context, in FY24, EV players were listing at an average P/E of 25x. We're seeing a similar trend of moderation across retail, textiles, and chemicals. ADVERTISEMENT In FY24, a staggering 242 companies went public, and many are now facing headwinds in the secondary market—about 40% of them are currently trading below their offer contrast to the last three years, we're now seeing IPOs that offer both value and growth, leaving sufficient room for valuation of comfort. This was a rarity in the overheated market of the recent past. Q) What is the initial sense you are picking up from the June quarter results, which have started to come out? ADVERTISEMENT A) Commodity-focused companies are performing exceptionally well, whereas service-oriented players are struggling to post positive results. Major players in cables, petrochemicals, and steel are reporting splendid results, especially on the bottom line, thanks to improved anticipate a strong earnings season for chemical companies, driven by an uptick in exports of specialty molecules to the US, new chemistries coming online for some major players, and expanding we expect the broader markets to show strong performance with revenue growth in the early teens and improving margins. However, our outlook for the Nifty 50 companies specifically is more tepid. Q) Is the current equity market rally largely liquidity-driven, or are there sufficient earnings fundamentals to back the optimism? A) It's mostly liquidity-driven. While we do expect earnings to be positive, the overall valuations remain expensive. Citibank wasn't wrong to downgrade the Indian markets. We have already shifted to cash in our model micro and small-cap oriented "Super 30" fund currently has a 25% cash holding, its highest in 10 months. The last time we exceeded this level was last are plenty of fundamentally strong companies with bright prospects, but the dilemma is that their current valuations already reflect their bullish performance for the next two to three years. Q) SIPs crossed Rs27K – what does it talk about the retail investor behaviour change? A) These are very positive signs. Instead of trying to time the markets or solely relying on a 'buy the dip' strategy, investors are demonstrating a greater inclination towards disciplined equity funds experience volatility, investors are now flocking to hybrid and arbitrage funds rather than abandoning the markets altogether. This behaviour is definitely changing for the better. Q) How is the corporate bond market shaping up here in India? A) At its current stage, the size of the Indian corporate bond market is negligible. To put it in perspective, while the US has a $14 trillion corporate bond market, ours is just $500 billion in with the rise of online bond platforms, lower ticket sizes of ₹10,000, and better yields for investors compared to fixed deposits, the corporate bond market is poised to grow by leaps and bounds from increasing issuance of higher credit ratings and the improved balance sheets of corporates further support the case for growth in corporate bond issuance. Q) Where are the pockets of opportunities coming from? A) We're finding opportunities in chemicals, automobile components, and select corporate turnarounds. Our sectoral exposure is varied, with no allocation to banking or IT at the moment. With chemical exports rising and price realizations improving, we continue to add names in this auto component space is a highly debated one. While many automakers are struggling with sales de-growth, auto volumes are still growing in specific regions, both abroad and auto component players we invest in are trading at a 16x price-to-earnings multiple, while we expect them to grow by a factor of 20-25%. Q) Where is the smart money moving? A) Lately, FII equity exposure has been shifting towards the Telecom and Financial sectors, while moving out of FMCG and Capital Goods. We expect this trend to continue if overall consumption remains investment circles, the defence industry has become more appealing, given the growth on both the export and domestic fronts. The challenge here is that there are far too many funds chasing a limited number of small stocks in the defence space. Q) How should one play the small & midcap space? A) When investing in any mid or small-cap stock, you must be prepared to stomach a 40% fall, regardless of how fundamentally strong the company is. This is a long-term game with the potential for higher returns, but it comes with higher risk. There are many exogenous factors at play that you'll have no control over, no matter how skilled you instance, Nectar Lifesciences, a small-cap company, baffled investors this July by deciding to sell off its entire business. This is just one example. It's ideal to have at least 15 stocks in your portfolio if you're aiming to invest in this you prefer the relative stability of the large-cap space, you should be fine with a more concentrated 10-stock portfolio. (Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
India.com
20 minutes ago
- India.com
This Indian company buys popular whiskey brand Imperial Blue for Rs 41500000000, biggest deals in India's liquor business, it is..., famous for...
Tilaknagar Industries is buying the popular whiskey brand Imperial Blue . The company has signed a final agreement with the Indian arm of French liquor giant Pernod Ricard to purchase the Imperial Blue business for Rs. 4,150 crore. Tilaknagar is already well-known for making Mansion House brandy, which is the best-selling brandy in India and the second-largest brandy brand in the world. The company said that buying Imperial Blue is a big step toward building its business across India in the IMFL (Indian Made Foreign Liquor) market. According to the company, 'This deal marks our entry into the Indian whiskey market. With this move, we will now be a key player in both major IMFL categories, brandy and whiskey.' They also said that the deal will help them grow their premium product range and make their supply network across the country even stronger. What did Pernod Ricard say about the deal? Pernod Ricard called this deal an important part of reshaping its product lineup. The company said, 'Selling Imperial Blue will allow us to focus more on premium brands in fast-growing markets like India. This move will also help improve our profit margins and boost our overall sales.' Chairman and CEO Alexandre Ricard said, 'This deal fits perfectly with our global plan—to focus on faster-growing and more profitable brands. It will also help us grow even stronger in an important market like India.' Deal not yet final, some approvals still needed The deal between Tilaknagar Industries and Pernod Ricard is not fully complete yet. It still needs approval from the Competition Commission of India (CCI). The deal is expected to be fully completed in the coming months. Back in December 2023, reports had said that both Tilaknagar and Inbrew Beverages were in the final race to buy Imperial Blue. Global investment firm Goldman Sachs acted as the advisor for Pernod Ricard in this deal. Tilaknagar's shares jump After news of the deal came out, Tilaknagar Industries' stock price went up sharply. In the last one month alone, the company's shares have jumped nearly 31 per cent. Tilaknagar already has a range of liquor brands in its portfolio, such as Mansion House Gold Barrel whiskey , Blue Lagoon gin , and Madira Gold Dark XXX rum . Big deals in India's alcohol industry This is one of the biggest deals in India's liquor business. Earlier in 2022, United Spirits (the Indian unit of Diageo) sold 32 brands, including Haywards , Old Tavern , and Green Label , to Inbrew Beverages for USD 106 million. Before that, the biggest deal in the Indian liquor industry happened in 2014, when Diageo bought United Spirits for about USD 1.9 billion.
India Today
23 minutes ago
- India Today
Intel layoffs: 25,000 roles at risk as company braces for big reset, says report
Intel plans to cut more than 25,000 jobs as the chipmaker prepares for a major reset, reported The New York Times. The company aims to reduce its workforce to about 75,000 employees by the end of 2025, down from 108,900 at the end of last report says the job cuts will come through a mix of layoffs, attrition, and other actions. Intel had already reduced its workforce by nearly 15%, or about 15,000 roles, since April 2025. This comes after more than 15,000 job cuts last confirmed the scale of the layoffs while releasing its financial results for the second quarter of 2025. The company posted a net loss of USD 2.9 billion, which included restructuring costs related to the latest downsizing. Revenue for the quarter was flat at USD 12.9 billion, which still beat market now expects revenue for the current quarter to be between USD 12.6 billion and USD 13.6 billion, with a midpoint of USD 13.1 billion. This is higher than the average forecast of USD 12.6 billion for the September quarter, as per analysts tracked by The New York a letter to employees, Intel's new CEO Lip-Bu Tan acknowledged the difficult period the company is going through. 'I know the past few months have not been easy,' he wrote. 'We are making hard but necessary decisions to streamline the organisation, drive greater efficiency and increase accountability at every level of the company.'The company has also shelved plans to build new factories in Germany and Poland. It will slow down the pace of construction at its Ohio site and consolidate some operations in Costa Rica by shifting them to Vietnam and Malaysia. Intel said these moves are part of a broader effort to reduce its operating costs and improve efficiency across its global April, the company announced plans to cut its annual operating expenses from USD 17.5 billion to USD 17 billion in 2025 and down to USD 16 billion by 2026. On Thursday, Intel said it remains on track to meet those once a leader in the global chip market, has struggled in recent years. While it dominated the microprocessor business during the personal computer boom of the 1990s, it missed the rise of smartphones and has fallen behind in the fast-growing artificial intelligence chip segment now led by companies like Tan, a venture capitalist and former Intel board member, took over as CEO in March. He has promised to cut through the company's bureaucracy and make its products more competitive. But he has also admitted that turning the company around will take of the key concerns for investors is the performance of Intel's latest production process, known as 18A. The previous CEO, Patrick Gelsinger, had claimed this technology would bring Intel up to the level of the most advanced chips made by Taiwan Semiconductor Manufacturing Company (TSMC). However, current Intel executives have stopped making such claims, though the technology remains important to the company's future chip also spoke of plans for a next-generation chip process called 14A. He said Intel will be more careful this time and will not build new factories without firm orders from outside customers.'Over the past several years, the company invested too much, too soon — without adequate demand,' Tan said in his letter to staff. 'In the process, our factory footprint became needlessly fragmented and underutilised. We must correct our course.'Intel's stock has faced pressure due to ongoing losses and slower innovation compared to its peers. Industry analysts believe the company will need to show faster progress in its manufacturing process and regain market share in AI chips to regain investor confidence.- Ends advertisement
